data_5j6w_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5j6w _Structure_validation_residue.Date_analyzed 2017-04-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.181 0.515 . . . . 0.0 110.158 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 6.3 pt -132.07 37.0 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.301 -0.874 . . . . 0.0 110.302 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.51 114.26 18.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.312 -0.868 . . . . 0.0 110.112 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.41 ' N ' ' CD1' ' A' ' 6' ' ' ILE . . . -70.37 -98.56 0.05 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -97.57 59.63 1.53 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.412 -1.052 . . . . 0.0 110.327 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.424 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 3.2 mp -98.57 -44.69 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 109.928 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.567 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 56.8 m95 -70.58 -47.72 17.53 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.441 -0.787 . . . . 0.0 110.91 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.567 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 30.1 Cg_endo -69.28 -32.55 20.35 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 O-C-N 123.17 1.089 . . . . 0.0 110.54 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tt -75.18 -22.58 57.92 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 110.477 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.46 -64.45 0.95 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.265 -0.897 . . . . 0.0 110.307 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.7 pp -61.65 -24.8 66.97 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.336 -0.852 . . . . 0.0 110.351 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.32 98.53 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.89 -19.67 43.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.384 -1.068 . . . . 0.0 110.433 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.69 -55.34 24.11 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.282 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.83 -30.88 66.11 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.35 -0.844 . . . . 0.0 110.532 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -60.58 -20.09 59.49 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.302 -0.874 . . . . 0.0 110.378 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 55.9 mt -99.64 -63.02 1.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.265 -0.897 . . . . 0.0 110.124 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.4 pt -61.45 -29.87 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.462 -0.774 . . . . 0.0 110.357 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 mmtt -119.83 146.93 45.26 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.372 -0.83 . . . . 0.0 110.226 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.338 0 O-C-N 119.901 -1.75 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.23 0.538 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.5 mp -100.39 -25.0 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.342 -0.849 . . . . 0.0 110.154 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.426 ' HB3' ' HB ' ' A' ' 6' ' ' ILE . 23.4 m-85 -99.91 150.6 22.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 110.094 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -105.18 -81.29 1.46 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.01 37.67 1.03 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.272 -1.134 . . . . 0.0 110.796 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.426 ' HB ' ' HB3' ' A' ' 3' ' ' PHE . 2.8 mp -95.66 -37.11 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.225 -0.922 . . . . 0.0 109.853 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.585 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 68.2 m95 -67.4 -47.94 47.04 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.493 -0.754 . . . . 0.0 110.657 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 25.5 Cg_endo -67.16 -28.03 41.05 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 O-C-N 123.15 1.079 . . . . 0.0 110.385 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.01 -29.62 49.6 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.358 -0.839 . . . . 0.0 110.189 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -80.72 -28.15 36.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.386 -0.821 . . . . 0.0 110.301 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.9 mt -90.24 -24.81 20.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.293 -0.879 . . . . 0.0 110.36 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -80.37 -30.04 42.55 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.75 -25.82 56.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 110.394 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.98 -57.63 7.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.34 -0.85 . . . . 0.0 110.152 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.77 -24.77 67.05 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.373 -0.83 . . . . 0.0 110.33 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -59.62 -27.35 66.24 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.334 -0.854 . . . . 0.0 110.323 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.2 mt -92.34 -63.98 1.17 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -0.902 . . . . 0.0 110.138 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.4 pt -62.16 -27.77 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.215 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.9 mmtt -130.53 -178.52 4.81 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 110.225 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.343 0 O-C-N 119.837 -1.79 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.229 0.538 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.7 mp -91.62 -34.19 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.321 -0.862 . . . . 0.0 109.938 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -100.19 135.99 40.78 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.478 -0.764 . . . . 0.0 110.044 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.89 -117.43 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.44 55.56 3.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.297 -1.119 . . . . 0.0 110.33 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CD1' ' N ' ' A' ' 6' ' ' ILE . 3.1 mp -98.15 -44.56 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.319 -0.863 . . . . 0.0 110.046 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.573 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 70.7 m95 -65.6 -48.19 65.67 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.345 -0.847 . . . . 0.0 110.932 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.573 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 29.1 Cg_endo -68.48 -31.5 27.25 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.236 1.124 . . . . 0.0 110.454 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 8.9 tt -74.69 -24.82 58.84 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.278 -0.889 . . . . 0.0 110.417 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.16 -66.86 0.79 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.219 -0.925 . . . . 0.0 110.284 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.6 pp -63.02 -25.15 68.25 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.361 -0.837 . . . . 0.0 110.446 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.27 -46.9 85.18 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -70.79 -24.31 62.55 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.342 -1.093 . . . . 0.0 110.432 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.5 tp -60.49 -63.32 1.34 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.268 -0.895 . . . . 0.0 110.357 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -26.77 66.94 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.337 -0.852 . . . . 0.0 110.456 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -59.84 -27.41 66.61 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.381 -0.824 . . . . 0.0 110.341 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 mt -92.07 -63.63 1.22 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.351 -0.843 . . . . 0.0 110.118 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.42 HG23 HD11 ' A' ' 18' ' ' ILE . 45.5 pt -61.77 -28.31 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.435 -0.79 . . . . 0.0 110.332 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -132.43 37.05 3.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.221 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.336 0 O-C-N 119.882 -1.761 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 40.9 mttt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.245 0.545 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 13.6 tt -65.12 -17.31 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.311 -0.868 . . . . 0.0 110.37 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.42 ' HB3' ' HB ' ' A' ' 6' ' ' ILE . 39.7 m-85 -126.08 147.55 49.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.208 -0.932 . . . . 0.0 110.265 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -86.55 -105.09 0.79 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.79 49.23 1.69 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.391 -1.064 . . . . 0.0 110.701 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 3' ' ' PHE . 2.9 mp -94.95 -29.11 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.346 -0.846 . . . . 0.0 109.769 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 68.3 m95 -71.57 -47.76 12.56 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 110.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 32.2 Cg_endo -70.23 -23.67 28.38 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.259 1.136 . . . . 0.0 110.143 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.6 tp -79.67 -42.21 25.26 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.417 -0.802 . . . . 0.0 110.136 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.05 -37.48 84.15 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.424 -0.797 . . . . 0.0 110.186 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.1 mt -64.09 -35.26 80.16 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.43 -0.794 . . . . 0.0 110.132 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.59 -30.06 75.8 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.69 -18.93 50.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -1.124 . . . . 0.0 110.436 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.3 tp -61.06 -66.07 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.233 -0.917 . . . . 0.0 110.251 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.81 62.69 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.379 -0.826 . . . . 0.0 110.417 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.23 -29.01 63.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.265 -0.897 . . . . 0.0 110.354 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 55.2 mt -88.03 -65.02 1.06 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.247 -0.908 . . . . 0.0 110.249 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 pt -60.81 -28.22 42.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.331 -0.856 . . . . 0.0 110.308 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.1 mmtt -128.29 41.53 3.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.398 -0.814 . . . . 0.0 110.12 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.379 0 O-C-N 119.859 -1.776 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.146 0.498 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 14.0 tt -115.33 -18.07 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 110.512 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.422 ' HB3' ' HB ' ' A' ' 6' ' ' ILE . 40.8 m-85 -126.14 -76.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 -179.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.83 -111.69 1.98 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.06 39.64 1.05 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -1.065 . . . . 0.0 110.325 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.422 ' HB ' ' HB3' ' A' ' 3' ' ' PHE . 2.3 mp -94.08 -35.4 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.349 -0.844 . . . . 0.0 109.809 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.577 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 58.2 m95 -69.16 -47.83 28.08 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.478 -0.764 . . . . 0.0 110.719 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 28.8 Cg_endo -68.47 -24.23 36.62 Favored 'Trans proline' 0 C--N 1.317 -1.103 0 O-C-N 123.17 1.089 . . . . 0.0 110.344 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 40.3 tp -58.58 -38.08 77.15 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.323 -0.86 . . . . 0.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -72.84 -39.32 66.65 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.345 -0.847 . . . . 0.0 110.2 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -63.94 -27.24 69.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.424 -0.798 . . . . 0.0 110.261 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -38.18 95.42 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.59 -24.02 42.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.414 -1.05 . . . . 0.0 110.274 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.1 tt -62.41 -54.35 41.52 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.373 -0.829 . . . . 0.0 110.222 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.87 -26.85 68.97 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -61.54 -18.45 59.27 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.243 -0.91 . . . . 0.0 110.365 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 47.7 mt -84.32 -65.75 0.97 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.306 -0.871 . . . . 0.0 110.288 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.437 HG13 ' N ' ' A' ' 19' ' ' LYS . 27.6 pt -79.62 -36.13 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.43 -0.794 . . . . 0.0 110.472 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.437 ' N ' HG13 ' A' ' 18' ' ' ILE . 1.7 mttp -105.32 83.42 1.96 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.346 -0.846 . . . . 0.0 110.136 -179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.841 -1.787 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.675 0 CA-C-O 121.13 0.49 . . . . 0.0 110.172 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 2' ' ' ILE . 13.8 tt -114.13 -17.2 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.383 -0.823 . . . . 0.0 110.433 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -138.53 148.23 44.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.189 -0.945 . . . . 0.0 110.162 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -77.43 -115.88 0.17 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -86.31 52.78 2.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.346 -1.091 . . . . 0.0 110.539 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.0 mp -94.7 -41.54 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.396 -0.815 . . . . 0.0 109.99 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.571 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 70.7 m95 -65.79 -48.64 62.56 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.436 -0.79 . . . . 0.0 110.829 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 22.4 Cg_endo -66.62 -27.03 45.86 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.31 1.163 . . . . 0.0 110.434 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.3 tp -62.04 -39.62 92.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.285 -0.884 . . . . 0.0 110.252 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.95 64.47 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.323 -0.861 . . . . 0.0 110.428 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.3 tp -92.46 -25.6 18.36 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.871 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.97 -27.48 73.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.89 -30.69 24.19 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.126 . . . . 0.0 110.287 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.1 mp -64.07 -45.33 89.24 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.353 -0.842 . . . . 0.0 110.238 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.17 -26.21 66.54 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.368 -0.833 . . . . 0.0 110.481 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -63.26 -21.05 65.99 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 110.529 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 62.3 mt -96.62 -63.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 110.422 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 pt -71.23 -28.3 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.339 -0.851 . . . . 0.0 110.497 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -119.11 26.07 9.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.301 -0.874 . . . . 0.0 110.249 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.366 0 O-C-N 119.851 -1.78 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.197 0.522 . . . . 0.0 110.208 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.423 HG21 ' CD2' ' A' ' 3' ' ' PHE . 14.1 tt -65.81 -20.56 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.392 -0.817 . . . . 0.0 110.388 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.461 ' CD2' ' CD1' ' A' ' 6' ' ' ILE . 34.6 m-85 -114.38 -161.16 0.76 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.226 -0.921 . . . . 0.0 109.979 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.81 -43.19 0.08 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -109.34 20.93 17.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.386 -1.067 . . . . 0.0 110.412 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.505 ' CD1' ' CE2' ' A' ' 7' ' ' TRP . 36.8 pt -91.29 -26.42 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.215 -0.928 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.595 ' HB2' ' HD3' ' A' ' 8' ' ' PRO . 12.0 m95 -85.27 -45.03 0.65 Allowed Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.608 -0.682 . . . . 0.0 110.13 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.595 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 14.0 Cg_exo -65.83 -19.6 58.74 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.349 1.184 . . . . 0.0 109.787 179.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.6 mt -84.16 -24.09 30.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 110.167 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -82.24 -34.09 28.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.263 -0.898 . . . . 0.0 110.218 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -61.99 -41.67 98.29 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.468 -0.77 . . . . 0.0 110.202 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.5 -30.11 75.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -71.71 -26.16 62.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.354 -1.086 . . . . 0.0 110.286 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.5 tp -61.69 -62.36 1.86 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.338 -0.851 . . . . 0.0 110.255 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.1 -23.01 65.17 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.368 -0.833 . . . . 0.0 110.381 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -61.85 -27.81 69.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.287 -0.883 . . . . 0.0 110.178 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 63.3 mt -91.11 -64.21 1.16 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.37 -0.831 . . . . 0.0 110.028 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 43.9 pt -60.19 -27.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.464 -0.773 . . . . 0.0 110.253 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 33.9 mmtm -131.45 41.66 3.28 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.393 -0.817 . . . . 0.0 110.234 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.38 0 O-C-N 120.031 -1.668 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.206 0.527 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.3 tt -103.97 -24.49 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.334 -0.854 . . . . 0.0 110.327 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.465 ' CG ' HD12 ' A' ' 6' ' ' ILE . 29.8 m-85 -129.11 -39.95 1.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.26 -0.9 . . . . 0.0 110.295 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 117.25 49.73 0.4 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.87 47.53 24.52 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -1.062 . . . . 0.0 110.534 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.466 ' CD1' ' CE2' ' A' ' 7' ' ' TRP . 28.5 pt -89.46 -19.56 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 110.622 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.606 ' HB2' ' HD3' ' A' ' 8' ' ' PRO . 10.1 m95 -87.99 -45.52 0.48 Allowed Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 110.285 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 11.3 Cg_exo -67.13 -17.5 50.63 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.269 1.141 . . . . 0.0 109.821 178.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.1 tt -89.12 -27.88 20.44 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.206 -0.934 . . . . 0.0 110.414 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.04 -28.84 43.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.314 -0.867 . . . . 0.0 110.325 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.36 -31.66 37.88 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.366 -0.834 . . . . 0.0 110.276 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.06 96.07 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.16 -20.88 47.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.391 -1.064 . . . . 0.0 110.392 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.96 -58.46 8.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 110.338 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -25.16 67.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -61.05 -27.68 68.52 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.251 -0.906 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.0 mt -85.62 -65.79 0.97 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.367 -0.833 . . . . 0.0 110.152 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -63.63 -26.78 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.395 -0.815 . . . . 0.0 110.198 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -131.51 -169.87 2.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.476 -0.765 . . . . 0.0 110.329 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.347 0 O-C-N 119.879 -1.763 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.143 0.497 . . . . 0.0 110.256 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.434 HG13 ' CD1' ' A' ' 3' ' ' PHE . 28.8 pt -120.62 -31.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.362 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.438 ' CG ' HD12 ' A' ' 6' ' ' ILE . 28.5 m-85 -125.99 164.26 21.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.224 -0.923 . . . . 0.0 110.026 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.91 -48.5 0.08 OUTLIER Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.76 40.31 3.75 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.227 -1.161 . . . . 0.0 110.595 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.501 ' CD1' ' CE2' ' A' ' 7' ' ' TRP . 31.6 pt -91.05 -24.48 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.59 ' HB2' ' HD3' ' A' ' 8' ' ' PRO . 11.6 m95 -86.0 -45.23 0.6 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.559 -0.713 . . . . 0.0 110.164 -179.589 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.59 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 13.4 Cg_exo -65.62 -19.57 60.06 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.406 1.214 . . . . 0.0 109.764 179.011 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.9 tt -75.0 -37.57 61.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.254 -0.904 . . . . 0.0 110.156 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.75 -46.7 57.64 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.349 -0.845 . . . . 0.0 110.098 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 mt -62.52 -27.38 69.11 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.313 -0.867 . . . . 0.0 110.108 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.31 -27.64 71.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.87 -21.17 57.45 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.346 -1.09 . . . . 0.0 110.336 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.3 tp -61.34 -59.01 5.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.204 -0.935 . . . . 0.0 110.282 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.32 -25.94 67.47 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.339 -0.851 . . . . 0.0 110.425 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -60.79 -23.76 65.27 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.293 -0.88 . . . . 0.0 110.271 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.3 mt -87.73 -64.78 1.1 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.137 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 45.8 pt -65.75 -28.93 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.355 -0.841 . . . . 0.0 110.306 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.2 mmtt -126.75 86.61 2.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.37 0 O-C-N 119.837 -1.789 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.19 0.519 . . . . 0.0 110.263 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 6.8 tp -113.03 -25.41 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.309 -0.869 . . . . 0.0 110.2 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -139.73 133.56 30.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.324 -0.86 . . . . 0.0 110.155 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.402 ' N ' ' CD1' ' A' ' 6' ' ' ILE . . . -74.86 -110.56 0.09 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.56 56.56 3.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.462 -1.023 . . . . 0.0 110.535 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.411 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 3.2 mp -96.89 -45.23 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.296 -0.878 . . . . 0.0 109.929 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.583 ' HB2' ' HD3' ' A' ' 8' ' ' PRO . 58.0 m95 -66.21 -42.9 52.83 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.349 -0.844 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.583 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 16.5 Cg_exo -63.88 -35.71 54.38 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 O-C-N 123.273 1.144 . . . . 0.0 109.963 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.6 tp -72.2 -32.11 66.48 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.42 -0.8 . . . . 0.0 110.07 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.42 -27.66 69.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.443 -0.786 . . . . 0.0 110.144 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.5 mt -79.78 -33.76 40.31 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.361 -0.837 . . . . 0.0 110.206 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.4 -30.84 78.97 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.22 -26.69 60.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.371 -1.076 . . . . 0.0 110.179 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.36 -67.59 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.338 -0.851 . . . . 0.0 110.139 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.434 ' O ' ' CG ' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -54.6 -29.68 52.44 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 110.234 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -53.57 -24.37 13.53 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.277 -0.89 . . . . 0.0 110.456 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 63.2 mt -80.23 -54.67 5.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.248 -0.907 . . . . 0.0 110.387 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.8 pt -78.29 -30.33 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.397 -0.814 . . . . 0.0 110.874 -179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.434 ' CG ' ' O ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -77.06 155.55 32.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 -179.58 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.848 -1.782 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.181 0.515 . . . . 0.0 110.158 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 6.3 pt -132.07 37.0 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.301 -0.874 . . . . 0.0 110.302 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.557 ' C ' HD13 ' A' ' 6' ' ' ILE . 92.4 m-85 -125.51 114.26 18.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.312 -0.868 . . . . 0.0 110.112 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.447 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -70.37 -98.56 0.05 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -97.57 59.63 1.53 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.412 -1.052 . . . . 0.0 110.327 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.641 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp -98.57 -44.69 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 109.928 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.586 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 56.8 m95 -70.58 -47.72 17.53 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.441 -0.787 . . . . 0.0 110.91 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 30.1 Cg_endo -69.28 -32.55 20.35 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 O-C-N 123.17 1.089 . . . . 0.0 110.54 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tt -75.18 -22.58 57.92 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 110.477 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.46 -64.45 0.95 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.265 -0.897 . . . . 0.0 110.307 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.7 pp -61.65 -24.8 66.97 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.336 -0.852 . . . . 0.0 110.351 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.32 98.53 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.89 -19.67 43.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.384 -1.068 . . . . 0.0 110.433 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.69 -55.34 24.11 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.282 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.83 -30.88 66.11 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.35 -0.844 . . . . 0.0 110.532 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -60.58 -20.09 59.49 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.302 -0.874 . . . . 0.0 110.378 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 55.9 mt -99.64 -63.02 1.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.265 -0.897 . . . . 0.0 110.124 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.406 HG13 ' N ' ' A' ' 19' ' ' LYS . 44.4 pt -61.45 -29.87 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.462 -0.774 . . . . 0.0 110.357 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.406 ' N ' HG13 ' A' ' 18' ' ' ILE . 22.5 mmtt -119.83 146.93 45.26 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.372 -0.83 . . . . 0.0 110.226 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.338 0 O-C-N 119.901 -1.75 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.23 0.538 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.469 ' H ' HD12 ' A' ' 2' ' ' ILE . 3.5 mp -100.39 -25.0 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.342 -0.849 . . . . 0.0 110.154 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.546 ' HB3' HD13 ' A' ' 6' ' ' ILE . 23.4 m-85 -99.91 150.6 22.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 110.094 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -105.18 -81.29 1.46 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.429 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -93.01 37.67 1.03 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.272 -1.134 . . . . 0.0 110.796 -179.367 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.632 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.8 mp -95.66 -37.11 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.225 -0.922 . . . . 0.0 109.853 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.602 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 68.2 m95 -67.4 -47.94 47.04 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.493 -0.754 . . . . 0.0 110.657 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.602 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 25.5 Cg_endo -67.16 -28.03 41.05 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 O-C-N 123.15 1.079 . . . . 0.0 110.385 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.429 HD12 ' O ' ' A' ' 5' ' ' ALA . 3.5 mt -78.01 -29.62 49.6 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.358 -0.839 . . . . 0.0 110.189 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -80.72 -28.15 36.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.386 -0.821 . . . . 0.0 110.301 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.9 mt -90.24 -24.81 20.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.293 -0.879 . . . . 0.0 110.36 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -80.37 -30.04 42.55 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.75 -25.82 56.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 110.394 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.98 -57.63 7.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.34 -0.85 . . . . 0.0 110.152 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.77 -24.77 67.05 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.373 -0.83 . . . . 0.0 110.33 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -59.62 -27.35 66.24 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.334 -0.854 . . . . 0.0 110.323 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.2 mt -92.34 -63.98 1.17 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -0.902 . . . . 0.0 110.138 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.4 pt -62.16 -27.77 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.215 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.9 mmtt -130.53 -178.52 4.81 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 110.225 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.343 0 O-C-N 119.837 -1.79 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.229 0.538 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.492 ' H ' HD12 ' A' ' 2' ' ' ILE . 2.7 mp -91.62 -34.19 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.321 -0.862 . . . . 0.0 109.938 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.517 ' HB3' HD13 ' A' ' 6' ' ' ILE . 67.8 m-85 -100.19 135.99 40.78 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.478 -0.764 . . . . 0.0 110.044 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.591 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -64.89 -117.43 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.44 55.56 3.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.297 -1.119 . . . . 0.0 110.33 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.624 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.1 mp -98.15 -44.56 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.319 -0.863 . . . . 0.0 110.046 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.592 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 70.7 m95 -65.6 -48.19 65.67 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.345 -0.847 . . . . 0.0 110.932 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 29.1 Cg_endo -68.48 -31.5 27.25 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.236 1.124 . . . . 0.0 110.454 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 8.9 tt -74.69 -24.82 58.84 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.278 -0.889 . . . . 0.0 110.417 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.16 -66.86 0.79 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.219 -0.925 . . . . 0.0 110.284 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.6 pp -63.02 -25.15 68.25 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.361 -0.837 . . . . 0.0 110.446 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.27 -46.9 85.18 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -70.79 -24.31 62.55 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.342 -1.093 . . . . 0.0 110.432 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.5 tp -60.49 -63.32 1.34 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.268 -0.895 . . . . 0.0 110.357 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -26.77 66.94 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.337 -0.852 . . . . 0.0 110.456 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -59.84 -27.41 66.61 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.381 -0.824 . . . . 0.0 110.341 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 mt -92.07 -63.63 1.22 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.351 -0.843 . . . . 0.0 110.118 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 45.5 pt -61.77 -28.31 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.435 -0.79 . . . . 0.0 110.332 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -132.43 37.05 3.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.221 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.336 0 O-C-N 119.882 -1.761 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 40.9 mttt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.245 0.545 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.734 HG23 ' CD1' ' A' ' 3' ' ' PHE . 13.6 tt -65.12 -17.31 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.311 -0.868 . . . . 0.0 110.37 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.734 ' CD1' HG23 ' A' ' 2' ' ' ILE . 39.7 m-85 -126.08 147.55 49.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.208 -0.932 . . . . 0.0 110.265 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.513 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -86.55 -105.09 0.79 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.79 49.23 1.69 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.391 -1.064 . . . . 0.0 110.701 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.645 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.9 mp -94.95 -29.11 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.346 -0.846 . . . . 0.0 109.769 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.579 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 68.3 m95 -71.57 -47.76 12.56 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 110.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.579 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 32.2 Cg_endo -70.23 -23.67 28.38 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.259 1.136 . . . . 0.0 110.143 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.6 tp -79.67 -42.21 25.26 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.417 -0.802 . . . . 0.0 110.136 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.05 -37.48 84.15 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.424 -0.797 . . . . 0.0 110.186 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.1 mt -64.09 -35.26 80.16 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.43 -0.794 . . . . 0.0 110.132 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.59 -30.06 75.8 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.69 -18.93 50.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -1.124 . . . . 0.0 110.436 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.3 tp -61.06 -66.07 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.233 -0.917 . . . . 0.0 110.251 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.81 62.69 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.379 -0.826 . . . . 0.0 110.417 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -57.23 -29.01 63.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.265 -0.897 . . . . 0.0 110.354 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 55.2 mt -88.03 -65.02 1.06 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.247 -0.908 . . . . 0.0 110.249 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.4 HG13 ' N ' ' A' ' 19' ' ' LYS . 46.3 pt -60.81 -28.22 42.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.331 -0.856 . . . . 0.0 110.308 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.4 ' N ' HG13 ' A' ' 18' ' ' ILE . 30.1 mmtt -128.29 41.53 3.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.398 -0.814 . . . . 0.0 110.12 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.379 0 O-C-N 119.859 -1.776 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.146 0.498 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.768 HG23 ' CD1' ' A' ' 3' ' ' PHE . 14.0 tt -115.33 -18.07 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 110.512 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.768 ' CD1' HG23 ' A' ' 2' ' ' ILE . 40.8 m-85 -126.14 -76.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 -179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.83 -111.69 1.98 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.06 39.64 1.05 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -1.065 . . . . 0.0 110.325 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.742 HD13 ' HB3' ' A' ' 3' ' ' PHE . 2.3 mp -94.08 -35.4 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.349 -0.844 . . . . 0.0 109.809 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.596 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 58.2 m95 -69.16 -47.83 28.08 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.478 -0.764 . . . . 0.0 110.719 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.596 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 28.8 Cg_endo -68.47 -24.23 36.62 Favored 'Trans proline' 0 C--N 1.317 -1.103 0 O-C-N 123.17 1.089 . . . . 0.0 110.344 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 40.3 tp -58.58 -38.08 77.15 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.323 -0.86 . . . . 0.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -72.84 -39.32 66.65 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.345 -0.847 . . . . 0.0 110.2 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.453 ' HA ' HD13 ' A' ' 11' ' ' LEU . 3.6 mm? -63.94 -27.24 69.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.424 -0.798 . . . . 0.0 110.261 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -38.18 95.42 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.59 -24.02 42.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.414 -1.05 . . . . 0.0 110.274 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.1 tt -62.41 -54.35 41.52 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.373 -0.829 . . . . 0.0 110.222 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.87 -26.85 68.97 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -61.54 -18.45 59.27 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.243 -0.91 . . . . 0.0 110.365 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 47.7 mt -84.32 -65.75 0.97 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.306 -0.871 . . . . 0.0 110.288 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.455 HG13 ' N ' ' A' ' 19' ' ' LYS . 27.6 pt -79.62 -36.13 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.43 -0.794 . . . . 0.0 110.472 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.455 ' N ' HG13 ' A' ' 18' ' ' ILE . 1.7 mttp -105.32 83.42 1.96 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.346 -0.846 . . . . 0.0 110.136 -179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.841 -1.787 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.675 0 CA-C-O 121.13 0.49 . . . . 0.0 110.172 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 13.8 tt -114.13 -17.2 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.383 -0.823 . . . . 0.0 110.433 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.553 ' HB3' HD13 ' A' ' 6' ' ' ILE . 14.2 m-85 -138.53 148.23 44.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.189 -0.945 . . . . 0.0 110.162 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.557 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -77.43 -115.88 0.17 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -86.31 52.78 2.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.346 -1.091 . . . . 0.0 110.539 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.619 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.0 mp -94.7 -41.54 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.396 -0.815 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.587 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 70.7 m95 -65.79 -48.64 62.56 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.436 -0.79 . . . . 0.0 110.829 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 22.4 Cg_endo -66.62 -27.03 45.86 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.31 1.163 . . . . 0.0 110.434 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.3 tp -62.04 -39.62 92.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.285 -0.884 . . . . 0.0 110.252 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.679 ' O ' HD13 ' A' ' 14' ' ' LEU . . . -68.53 -18.95 64.47 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.323 -0.861 . . . . 0.0 110.428 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.544 HD12 ' O ' ' A' ' 11' ' ' LEU . 5.3 tp -92.46 -25.6 18.36 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.871 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.97 -27.48 73.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.89 -30.69 24.19 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.126 . . . . 0.0 110.287 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.679 HD13 ' O ' ' A' ' 10' ' ' ALA . 3.1 mp -64.07 -45.33 89.24 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.353 -0.842 . . . . 0.0 110.238 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.17 -26.21 66.54 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.368 -0.833 . . . . 0.0 110.481 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -63.26 -21.05 65.99 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 110.529 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 62.3 mt -96.62 -63.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 110.422 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 pt -71.23 -28.3 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.339 -0.851 . . . . 0.0 110.497 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -119.11 26.07 9.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.301 -0.874 . . . . 0.0 110.249 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.366 0 O-C-N 119.851 -1.78 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.197 0.522 . . . . 0.0 110.208 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.661 HG23 ' CD2' ' A' ' 3' ' ' PHE . 14.1 tt -65.81 -20.56 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.392 -0.817 . . . . 0.0 110.388 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.803 ' CG ' HD13 ' A' ' 6' ' ' ILE . 34.6 m-85 -114.38 -161.16 0.76 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.226 -0.921 . . . . 0.0 109.979 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.81 -43.19 0.08 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.683 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -109.34 20.93 17.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.386 -1.067 . . . . 0.0 110.412 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.808 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 36.8 pt -91.29 -26.42 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.215 -0.928 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.808 ' CZ2' HD11 ' A' ' 6' ' ' ILE . 12.0 m95 -85.27 -45.03 0.65 Allowed Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.608 -0.682 . . . . 0.0 110.13 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.585 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 14.0 Cg_exo -65.83 -19.6 58.74 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.349 1.184 . . . . 0.0 109.787 179.195 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.683 HD12 ' O ' ' A' ' 5' ' ' ALA . 2.6 mt -84.16 -24.09 30.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 110.167 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -82.24 -34.09 28.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.263 -0.898 . . . . 0.0 110.218 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.451 ' HA ' HD13 ' A' ' 11' ' ' LEU . 3.2 mm? -61.99 -41.67 98.29 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.468 -0.77 . . . . 0.0 110.202 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.5 -30.11 75.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -71.71 -26.16 62.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.354 -1.086 . . . . 0.0 110.286 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.5 tp -61.69 -62.36 1.86 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.338 -0.851 . . . . 0.0 110.255 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.406 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -61.1 -23.01 65.17 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.368 -0.833 . . . . 0.0 110.381 -179.889 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -61.85 -27.81 69.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.287 -0.883 . . . . 0.0 110.178 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 63.3 mt -91.11 -64.21 1.16 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.37 -0.831 . . . . 0.0 110.028 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.406 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 43.9 pt -60.19 -27.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.464 -0.773 . . . . 0.0 110.253 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 33.9 mmtm -131.45 41.66 3.28 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.393 -0.817 . . . . 0.0 110.234 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.38 0 O-C-N 120.031 -1.668 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.206 0.527 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.538 HG23 ' CD2' ' A' ' 3' ' ' PHE . 15.3 tt -103.97 -24.49 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.334 -0.854 . . . . 0.0 110.327 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.538 ' CD2' HG23 ' A' ' 2' ' ' ILE . 29.8 m-85 -129.11 -39.95 1.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.26 -0.9 . . . . 0.0 110.295 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 117.25 49.73 0.4 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.87 47.53 24.52 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -1.062 . . . . 0.0 110.534 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.882 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 28.5 pt -89.46 -19.56 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 110.622 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.882 ' CZ2' HD11 ' A' ' 6' ' ' ILE . 10.1 m95 -87.99 -45.52 0.48 Allowed Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 110.285 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.595 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 11.3 Cg_exo -67.13 -17.5 50.63 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.269 1.141 . . . . 0.0 109.821 178.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.1 tt -89.12 -27.88 20.44 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.206 -0.934 . . . . 0.0 110.414 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.04 -28.84 43.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.314 -0.867 . . . . 0.0 110.325 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.36 -31.66 37.88 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.366 -0.834 . . . . 0.0 110.276 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.06 96.07 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.16 -20.88 47.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.391 -1.064 . . . . 0.0 110.392 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.96 -58.46 8.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 110.338 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -25.16 67.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -61.05 -27.68 68.52 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.251 -0.906 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.0 mt -85.62 -65.79 0.97 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.367 -0.833 . . . . 0.0 110.152 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -63.63 -26.78 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.395 -0.815 . . . . 0.0 110.198 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -131.51 -169.87 2.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.476 -0.765 . . . . 0.0 110.329 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.347 0 O-C-N 119.879 -1.763 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.143 0.497 . . . . 0.0 110.256 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.687 HD12 ' CE1' ' A' ' 3' ' ' PHE . 28.8 pt -120.62 -31.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.362 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.852 ' CG ' HD13 ' A' ' 6' ' ' ILE . 28.5 m-85 -125.99 164.26 21.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.224 -0.923 . . . . 0.0 110.026 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.91 -48.5 0.08 OUTLIER Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.76 40.31 3.75 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.227 -1.161 . . . . 0.0 110.595 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.852 HD13 ' CG ' ' A' ' 3' ' ' PHE . 31.6 pt -91.05 -24.48 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.846 ' CZ2' HD11 ' A' ' 6' ' ' ILE . 11.6 m95 -86.0 -45.23 0.6 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.559 -0.713 . . . . 0.0 110.164 -179.589 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.583 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 13.4 Cg_exo -65.62 -19.57 60.06 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.406 1.214 . . . . 0.0 109.764 179.011 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.9 tt -75.0 -37.57 61.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.254 -0.904 . . . . 0.0 110.156 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.75 -46.7 57.64 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.349 -0.845 . . . . 0.0 110.098 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 mt -62.52 -27.38 69.11 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.313 -0.867 . . . . 0.0 110.108 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.31 -27.64 71.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.87 -21.17 57.45 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.346 -1.09 . . . . 0.0 110.336 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.3 tp -61.34 -59.01 5.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.204 -0.935 . . . . 0.0 110.282 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.32 -25.94 67.47 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.339 -0.851 . . . . 0.0 110.425 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -60.79 -23.76 65.27 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.293 -0.88 . . . . 0.0 110.271 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.3 mt -87.73 -64.78 1.1 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.137 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 19' ' ' LYS . 45.8 pt -65.75 -28.93 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.355 -0.841 . . . . 0.0 110.306 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' N ' HG13 ' A' ' 18' ' ' ILE . 4.2 mmtt -126.75 86.61 2.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.37 0 O-C-N 119.837 -1.789 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.19 0.519 . . . . 0.0 110.263 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.469 HG23 ' CD2' ' A' ' 3' ' ' PHE . 6.8 tp -113.03 -25.41 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.309 -0.869 . . . . 0.0 110.2 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.55 ' HB3' HD13 ' A' ' 6' ' ' ILE . 36.2 m-85 -139.73 133.56 30.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.324 -0.86 . . . . 0.0 110.155 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.527 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -74.86 -110.56 0.09 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.56 56.56 3.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.462 -1.023 . . . . 0.0 110.535 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.619 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp -96.89 -45.23 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.296 -0.878 . . . . 0.0 109.929 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.565 ' HB2' ' HD3' ' A' ' 8' ' ' PRO . 58.0 m95 -66.21 -42.9 52.83 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.349 -0.844 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.565 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 16.5 Cg_exo -63.88 -35.71 54.38 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 O-C-N 123.273 1.144 . . . . 0.0 109.963 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.6 tp -72.2 -32.11 66.48 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.42 -0.8 . . . . 0.0 110.07 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.42 -27.66 69.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.443 -0.786 . . . . 0.0 110.144 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.5 mt -79.78 -33.76 40.31 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.361 -0.837 . . . . 0.0 110.206 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.4 -30.84 78.97 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.22 -26.69 60.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.371 -1.076 . . . . 0.0 110.179 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.36 -67.59 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.338 -0.851 . . . . 0.0 110.139 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.434 ' O ' ' CG ' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -54.6 -29.68 52.44 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 110.234 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -53.57 -24.37 13.53 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.277 -0.89 . . . . 0.0 110.456 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 63.2 mt -80.23 -54.67 5.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.248 -0.907 . . . . 0.0 110.387 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.8 pt -78.29 -30.33 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.397 -0.814 . . . . 0.0 110.874 -179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.434 ' CG ' ' O ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -77.06 155.55 32.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 -179.58 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.848 -1.782 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.181 0.515 . . . . 0.0 110.158 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 6.3 pt -132.07 37.0 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.301 -0.874 . . . . 0.0 110.302 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.557 ' C ' HD13 ' A' ' 6' ' ' ILE . 92.4 m-85 -125.51 114.26 18.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.312 -0.868 . . . . 0.0 110.112 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.447 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -70.37 -98.56 0.05 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -97.57 59.63 1.53 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.412 -1.052 . . . . 0.0 110.327 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.641 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp -98.57 -44.69 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 109.928 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.586 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 56.8 m95 -70.58 -47.72 17.53 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.441 -0.787 . . . . 0.0 110.91 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 30.1 Cg_endo -69.28 -32.55 20.35 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 O-C-N 123.17 1.089 . . . . 0.0 110.54 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tt -75.18 -22.58 57.92 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 110.477 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.46 -64.45 0.95 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.265 -0.897 . . . . 0.0 110.307 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.7 pp -61.65 -24.8 66.97 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.336 -0.852 . . . . 0.0 110.351 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.32 98.53 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.89 -19.67 43.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.384 -1.068 . . . . 0.0 110.433 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.69 -55.34 24.11 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.282 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.83 -30.88 66.11 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.35 -0.844 . . . . 0.0 110.532 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -60.58 -20.09 59.49 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.302 -0.874 . . . . 0.0 110.378 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 55.9 mt -99.64 -63.02 1.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.265 -0.897 . . . . 0.0 110.124 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.406 HG13 ' N ' ' A' ' 19' ' ' LYS . 44.4 pt -61.45 -29.87 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.462 -0.774 . . . . 0.0 110.357 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.406 ' N ' HG13 ' A' ' 18' ' ' ILE . 22.5 mmtt -119.83 146.93 45.26 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.372 -0.83 . . . . 0.0 110.226 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.338 0 O-C-N 119.901 -1.75 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.23 0.538 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.469 ' H ' HD12 ' A' ' 2' ' ' ILE . 3.5 mp -100.39 -25.0 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.342 -0.849 . . . . 0.0 110.154 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.546 ' HB3' HD13 ' A' ' 6' ' ' ILE . 23.4 m-85 -99.91 150.6 22.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 110.094 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -105.18 -81.29 1.46 Allowed Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.429 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -93.01 37.67 1.03 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.272 -1.134 . . . . 0.0 110.796 -179.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.632 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.8 mp -95.66 -37.11 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.225 -0.922 . . . . 0.0 109.853 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.602 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 68.2 m95 -67.4 -47.94 47.04 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.493 -0.754 . . . . 0.0 110.657 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.602 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 25.5 Cg_endo -67.16 -28.03 41.05 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 O-C-N 123.15 1.079 . . . . 0.0 110.385 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.429 HD12 ' O ' ' A' ' 5' ' ' ALA . 3.5 mt -78.01 -29.62 49.6 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.358 -0.839 . . . . 0.0 110.189 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -80.72 -28.15 36.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.386 -0.821 . . . . 0.0 110.301 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.9 mt -90.24 -24.81 20.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.293 -0.879 . . . . 0.0 110.36 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -80.37 -30.04 42.55 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.75 -25.82 56.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 110.394 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.98 -57.63 7.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.34 -0.85 . . . . 0.0 110.152 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.77 -24.77 67.05 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.373 -0.83 . . . . 0.0 110.33 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -59.62 -27.35 66.24 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.334 -0.854 . . . . 0.0 110.323 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.2 mt -92.34 -63.98 1.17 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -0.902 . . . . 0.0 110.138 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.4 pt -62.16 -27.77 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.215 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.9 mmtt -130.53 -178.52 4.81 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 110.225 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.343 0 O-C-N 119.837 -1.79 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.229 0.538 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.492 ' H ' HD12 ' A' ' 2' ' ' ILE . 2.7 mp -91.62 -34.19 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.321 -0.862 . . . . 0.0 109.938 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.517 ' HB3' HD13 ' A' ' 6' ' ' ILE . 67.8 m-85 -100.19 135.99 40.78 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.478 -0.764 . . . . 0.0 110.044 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.591 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -64.89 -117.43 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.44 55.56 3.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.297 -1.119 . . . . 0.0 110.33 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.624 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.1 mp -98.15 -44.56 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.319 -0.863 . . . . 0.0 110.046 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.592 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 70.7 m95 -65.6 -48.19 65.67 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.345 -0.847 . . . . 0.0 110.932 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 29.1 Cg_endo -68.48 -31.5 27.25 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.236 1.124 . . . . 0.0 110.454 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 8.9 tt -74.69 -24.82 58.84 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.278 -0.889 . . . . 0.0 110.417 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.16 -66.86 0.79 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.219 -0.925 . . . . 0.0 110.284 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.6 pp -63.02 -25.15 68.25 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.361 -0.837 . . . . 0.0 110.446 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.27 -46.9 85.18 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -70.79 -24.31 62.55 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.342 -1.093 . . . . 0.0 110.432 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.5 tp -60.49 -63.32 1.34 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.268 -0.895 . . . . 0.0 110.357 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -26.77 66.94 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.337 -0.852 . . . . 0.0 110.456 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -59.84 -27.41 66.61 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.381 -0.824 . . . . 0.0 110.341 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 mt -92.07 -63.63 1.22 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.351 -0.843 . . . . 0.0 110.118 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 45.5 pt -61.77 -28.31 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.435 -0.79 . . . . 0.0 110.332 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -132.43 37.05 3.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.221 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.336 0 O-C-N 119.882 -1.761 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 40.9 mttt . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.245 0.545 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.734 HG23 ' CD1' ' A' ' 3' ' ' PHE . 13.6 tt -65.12 -17.31 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.311 -0.868 . . . . 0.0 110.37 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.734 ' CD1' HG23 ' A' ' 2' ' ' ILE . 39.7 m-85 -126.08 147.55 49.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.208 -0.932 . . . . 0.0 110.265 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.513 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -86.55 -105.09 0.79 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.79 49.23 1.69 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.391 -1.064 . . . . 0.0 110.701 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.645 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.9 mp -94.95 -29.11 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.346 -0.846 . . . . 0.0 109.769 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.579 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 68.3 m95 -71.57 -47.76 12.56 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 110.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.579 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 32.2 Cg_endo -70.23 -23.67 28.38 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.259 1.136 . . . . 0.0 110.143 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.6 tp -79.67 -42.21 25.26 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.417 -0.802 . . . . 0.0 110.136 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.05 -37.48 84.15 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.424 -0.797 . . . . 0.0 110.186 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.1 mt -64.09 -35.26 80.16 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.43 -0.794 . . . . 0.0 110.132 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.59 -30.06 75.8 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.69 -18.93 50.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -1.124 . . . . 0.0 110.436 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.3 tp -61.06 -66.07 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.233 -0.917 . . . . 0.0 110.251 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.81 62.69 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.379 -0.826 . . . . 0.0 110.417 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.23 -29.01 63.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.265 -0.897 . . . . 0.0 110.354 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 55.2 mt -88.03 -65.02 1.06 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.247 -0.908 . . . . 0.0 110.249 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.4 HG13 ' N ' ' A' ' 19' ' ' LYS . 46.3 pt -60.81 -28.22 42.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.331 -0.856 . . . . 0.0 110.308 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.4 ' N ' HG13 ' A' ' 18' ' ' ILE . 30.1 mmtt -128.29 41.53 3.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.398 -0.814 . . . . 0.0 110.12 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.379 0 O-C-N 119.859 -1.776 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.146 0.498 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.768 HG23 ' CD1' ' A' ' 3' ' ' PHE . 14.0 tt -115.33 -18.07 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.342 -0.849 . . . . 0.0 110.512 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.768 ' CD1' HG23 ' A' ' 2' ' ' ILE . 40.8 m-85 -126.14 -76.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 -179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.83 -111.69 1.98 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.06 39.64 1.05 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -1.065 . . . . 0.0 110.325 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.742 HD13 ' HB3' ' A' ' 3' ' ' PHE . 2.3 mp -94.08 -35.4 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.349 -0.844 . . . . 0.0 109.809 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.596 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 58.2 m95 -69.16 -47.83 28.08 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.478 -0.764 . . . . 0.0 110.719 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.596 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 28.8 Cg_endo -68.47 -24.23 36.62 Favored 'Trans proline' 0 C--N 1.317 -1.103 0 O-C-N 123.17 1.089 . . . . 0.0 110.344 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 40.3 tp -58.58 -38.08 77.15 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.323 -0.86 . . . . 0.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -72.84 -39.32 66.65 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.345 -0.847 . . . . 0.0 110.2 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.453 ' HA ' HD13 ' A' ' 11' ' ' LEU . 3.6 mm? -63.94 -27.24 69.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.424 -0.798 . . . . 0.0 110.261 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -38.18 95.42 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.59 -24.02 42.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.414 -1.05 . . . . 0.0 110.274 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.1 tt -62.41 -54.35 41.52 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.373 -0.829 . . . . 0.0 110.222 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.87 -26.85 68.97 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -61.54 -18.45 59.27 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.243 -0.91 . . . . 0.0 110.365 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 47.7 mt -84.32 -65.75 0.97 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.306 -0.871 . . . . 0.0 110.288 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.455 HG13 ' N ' ' A' ' 19' ' ' LYS . 27.6 pt -79.62 -36.13 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.43 -0.794 . . . . 0.0 110.472 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.455 ' N ' HG13 ' A' ' 18' ' ' ILE . 1.7 mttp -105.32 83.42 1.96 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.346 -0.846 . . . . 0.0 110.136 -179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.841 -1.787 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.675 0 CA-C-O 121.13 0.49 . . . . 0.0 110.172 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 13.8 tt -114.13 -17.2 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.383 -0.823 . . . . 0.0 110.433 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.553 ' HB3' HD13 ' A' ' 6' ' ' ILE . 14.2 m-85 -138.53 148.23 44.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.189 -0.945 . . . . 0.0 110.162 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.557 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -77.43 -115.88 0.17 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -86.31 52.78 2.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.346 -1.091 . . . . 0.0 110.539 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.619 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.0 mp -94.7 -41.54 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.396 -0.815 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.587 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 70.7 m95 -65.79 -48.64 62.56 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.436 -0.79 . . . . 0.0 110.829 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 22.4 Cg_endo -66.62 -27.03 45.86 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.31 1.163 . . . . 0.0 110.434 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.3 tp -62.04 -39.62 92.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.285 -0.884 . . . . 0.0 110.252 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.679 ' O ' HD13 ' A' ' 14' ' ' LEU . . . -68.53 -18.95 64.47 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.323 -0.861 . . . . 0.0 110.428 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.544 HD12 ' O ' ' A' ' 11' ' ' LEU . 5.3 tp -92.46 -25.6 18.36 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.871 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.97 -27.48 73.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.89 -30.69 24.19 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.126 . . . . 0.0 110.287 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.679 HD13 ' O ' ' A' ' 10' ' ' ALA . 3.1 mp -64.07 -45.33 89.24 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.353 -0.842 . . . . 0.0 110.238 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.17 -26.21 66.54 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.368 -0.833 . . . . 0.0 110.481 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -63.26 -21.05 65.99 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 110.529 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 62.3 mt -96.62 -63.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 110.422 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 pt -71.23 -28.3 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.339 -0.851 . . . . 0.0 110.497 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -119.11 26.07 9.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.301 -0.874 . . . . 0.0 110.249 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.366 0 O-C-N 119.851 -1.78 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.197 0.522 . . . . 0.0 110.208 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.661 HG23 ' CD2' ' A' ' 3' ' ' PHE . 14.1 tt -65.81 -20.56 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.392 -0.817 . . . . 0.0 110.388 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.803 ' CG ' HD13 ' A' ' 6' ' ' ILE . 34.6 m-85 -114.38 -161.16 0.76 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.226 -0.921 . . . . 0.0 109.979 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.81 -43.19 0.08 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.683 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -109.34 20.93 17.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.386 -1.067 . . . . 0.0 110.412 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.808 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 36.8 pt -91.29 -26.42 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.215 -0.928 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.808 ' CZ2' HD11 ' A' ' 6' ' ' ILE . 12.0 m95 -85.27 -45.03 0.65 Allowed Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.608 -0.682 . . . . 0.0 110.13 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.585 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 14.0 Cg_exo -65.83 -19.6 58.74 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.349 1.184 . . . . 0.0 109.787 179.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.683 HD12 ' O ' ' A' ' 5' ' ' ALA . 2.6 mt -84.16 -24.09 30.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 110.167 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -82.24 -34.09 28.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.263 -0.898 . . . . 0.0 110.218 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.451 ' HA ' HD13 ' A' ' 11' ' ' LEU . 3.2 mm? -61.99 -41.67 98.29 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.468 -0.77 . . . . 0.0 110.202 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.5 -30.11 75.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -71.71 -26.16 62.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.354 -1.086 . . . . 0.0 110.286 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.5 tp -61.69 -62.36 1.86 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.338 -0.851 . . . . 0.0 110.255 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.406 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -61.1 -23.01 65.17 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.368 -0.833 . . . . 0.0 110.381 -179.889 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -61.85 -27.81 69.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.287 -0.883 . . . . 0.0 110.178 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 63.3 mt -91.11 -64.21 1.16 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.37 -0.831 . . . . 0.0 110.028 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.406 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 43.9 pt -60.19 -27.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.464 -0.773 . . . . 0.0 110.253 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 33.9 mmtm -131.45 41.66 3.28 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.393 -0.817 . . . . 0.0 110.234 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.38 0 O-C-N 120.031 -1.668 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.206 0.527 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.538 HG23 ' CD2' ' A' ' 3' ' ' PHE . 15.3 tt -103.97 -24.49 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.334 -0.854 . . . . 0.0 110.327 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.538 ' CD2' HG23 ' A' ' 2' ' ' ILE . 29.8 m-85 -129.11 -39.95 1.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.26 -0.9 . . . . 0.0 110.295 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 117.25 49.73 0.4 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.87 47.53 24.52 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -1.062 . . . . 0.0 110.534 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.882 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 28.5 pt -89.46 -19.56 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 110.622 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.882 ' CZ2' HD11 ' A' ' 6' ' ' ILE . 10.1 m95 -87.99 -45.52 0.48 Allowed Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 110.285 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.595 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 11.3 Cg_exo -67.13 -17.5 50.63 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.269 1.141 . . . . 0.0 109.821 178.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.1 tt -89.12 -27.88 20.44 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.206 -0.934 . . . . 0.0 110.414 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.04 -28.84 43.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.314 -0.867 . . . . 0.0 110.325 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.36 -31.66 37.88 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.366 -0.834 . . . . 0.0 110.276 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.06 96.07 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.16 -20.88 47.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.391 -1.064 . . . . 0.0 110.392 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.96 -58.46 8.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 110.338 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -25.16 67.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -61.05 -27.68 68.52 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.251 -0.906 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.0 mt -85.62 -65.79 0.97 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.367 -0.833 . . . . 0.0 110.152 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 pt -63.63 -26.78 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.395 -0.815 . . . . 0.0 110.198 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -131.51 -169.87 2.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.476 -0.765 . . . . 0.0 110.329 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.347 0 O-C-N 119.879 -1.763 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.143 0.497 . . . . 0.0 110.256 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.687 HD12 ' CE1' ' A' ' 3' ' ' PHE . 28.8 pt -120.62 -31.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.362 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.852 ' CG ' HD13 ' A' ' 6' ' ' ILE . 28.5 m-85 -125.99 164.26 21.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.224 -0.923 . . . . 0.0 110.026 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.91 -48.5 0.08 OUTLIER Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.76 40.31 3.75 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.227 -1.161 . . . . 0.0 110.595 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.852 HD13 ' CG ' ' A' ' 3' ' ' PHE . 31.6 pt -91.05 -24.48 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.251 -0.905 . . . . 0.0 110.258 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.846 ' CZ2' HD11 ' A' ' 6' ' ' ILE . 11.6 m95 -86.0 -45.23 0.6 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.559 -0.713 . . . . 0.0 110.164 -179.589 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.583 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 13.4 Cg_exo -65.62 -19.57 60.06 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.406 1.214 . . . . 0.0 109.764 179.011 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.9 tt -75.0 -37.57 61.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.254 -0.904 . . . . 0.0 110.156 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.75 -46.7 57.64 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.349 -0.845 . . . . 0.0 110.098 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 mt -62.52 -27.38 69.11 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.313 -0.867 . . . . 0.0 110.108 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.31 -27.64 71.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.87 -21.17 57.45 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.346 -1.09 . . . . 0.0 110.336 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.3 tp -61.34 -59.01 5.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.204 -0.935 . . . . 0.0 110.282 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.32 -25.94 67.47 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.339 -0.851 . . . . 0.0 110.425 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -60.79 -23.76 65.27 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.293 -0.88 . . . . 0.0 110.271 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.3 mt -87.73 -64.78 1.1 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.137 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 19' ' ' LYS . 45.8 pt -65.75 -28.93 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.355 -0.841 . . . . 0.0 110.306 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' N ' HG13 ' A' ' 18' ' ' ILE . 4.2 mmtt -126.75 86.61 2.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.37 0 O-C-N 119.837 -1.789 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.19 0.519 . . . . 0.0 110.263 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.469 HG23 ' CD2' ' A' ' 3' ' ' PHE . 6.8 tp -113.03 -25.41 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.309 -0.869 . . . . 0.0 110.2 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.55 ' HB3' HD13 ' A' ' 6' ' ' ILE . 36.2 m-85 -139.73 133.56 30.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.324 -0.86 . . . . 0.0 110.155 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.527 ' N ' HD13 ' A' ' 6' ' ' ILE . . . -74.86 -110.56 0.09 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.56 56.56 3.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.462 -1.023 . . . . 0.0 110.535 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.619 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp -96.89 -45.23 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.296 -0.878 . . . . 0.0 109.929 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.565 ' HB2' ' HD3' ' A' ' 8' ' ' PRO . 58.0 m95 -66.21 -42.9 52.83 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.349 -0.844 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.565 ' HD3' ' HB2' ' A' ' 7' ' ' TRP . 16.5 Cg_exo -63.88 -35.71 54.38 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 O-C-N 123.273 1.144 . . . . 0.0 109.963 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.6 tp -72.2 -32.11 66.48 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.42 -0.8 . . . . 0.0 110.07 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.42 -27.66 69.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.443 -0.786 . . . . 0.0 110.144 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.5 mt -79.78 -33.76 40.31 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.361 -0.837 . . . . 0.0 110.206 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.4 -30.84 78.97 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.22 -26.69 60.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.371 -1.076 . . . . 0.0 110.179 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.36 -67.59 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.338 -0.851 . . . . 0.0 110.139 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.434 ' O ' ' CG ' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -54.6 -29.68 52.44 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 110.234 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -53.57 -24.37 13.53 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.277 -0.89 . . . . 0.0 110.456 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 63.2 mt -80.23 -54.67 5.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.248 -0.907 . . . . 0.0 110.387 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.8 pt -78.29 -30.33 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.397 -0.814 . . . . 0.0 110.874 -179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.434 ' CG ' ' O ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -77.06 155.55 32.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 -179.58 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.848 -1.782 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_